Randomized, double-blind, placebo-controlled study vs data in the daily practice using linaclotide in patients with irritable bowel syndrome with constipation
Neurogastroenterol Motil
.
2018 May;30(5):e13363.
doi: 10.1111/nmo.13363.
Authors
S Fukudo
1
,
A Nakajima
2
,
Y Fujiyama
3
,
M Kosako
4
,
A Nakagawa
4
,
H Akiho
4
,
Y Nakashima
5
,
J M Johnston
6
,
H Miwa
7
Affiliations
1
Department of Behavioral Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
2
Department of Gastroenterology, Yokohama City University, Yokohama, Japan.
3
Shiga University of Medical Science, Ohtsu, Japan.
4
Japan-Asia Clinical Development 2, Development, Astellas Pharma Inc., Tokyo, Japan.
5
Japan-Asia Data Science, Development, Astellas Pharma Inc., Tokyo, Japan.
6
Ironwood Pharmaceuticals Inc., Cambridge, MA, USA.
7
Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
PMID:
29700962
DOI:
10.1111/nmo.13363
No abstract available
Publication types
Letter
Comment
MeSH terms
Constipation*
Double-Blind Method
Humans
Irritable Bowel Syndrome*
Japan
Peptides
Substances
Peptides
linaclotide